Adaptogen Export Market Intelligence: India's 1 Suppliers Shipping to 2 Countries — TransData Nexus 2026

Q: Who are the top adaptogen exporters from India?

The top adaptogen exporters from India are: 1. KERALA AYURVEDA LIMITED — $6.2K (100.0% market share). Together they account for 100.0% of India's total adaptogen export value.

Q: What is the total export value of adaptogen from India?

The total export value of adaptogen from India is $6.2K USD, recorded across 12 shipment transactions from 1 active exporters to 2 destination countries. The average shipment value is $516.

Q: Which countries import adaptogen from India?

India exports adaptogen to 2 countries worldwide. The top importing countries are: UNITED STATES (89.1% share, $5.5K), SINGAPORE (10.9% share, $674). These five markets account for 100.0% of total export value.

Q: What is the HS code for adaptogen exports from India?

The primary HS code for adaptogen exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of adaptogen exports from India?

The average unit price for adaptogen exports from India is $22.33 USD per unit, with prices ranging from $1.74 to $43.07 depending on formulation, packaging, and order volume. The total market is valued at $6.2K across 12 shipments.

Q: Which ports handle adaptogen exports from India?

The primary ports for adaptogen exports from India are COCHIN SEA (INCOK1) (50.0% of shipments), COCHIN AIR CARGO ACC (INCOK4) (16.7% of shipments), Bangalore Air (8.3% of shipments), Bangalore Icd (8.3% of shipments), BANGALORE ICD (8.3% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of adaptogen?

India is one of the world's leading exporters of adaptogen due to its large base of 1 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports adaptogen to 2 countries, demonstrating 1% global market coverage.

Q: What certifications do Indian adaptogen exporters need?

Indian adaptogen exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import adaptogen from India?

There are 5 registered buyers importing adaptogen from India, spread across 2 countries. The repeat buyer rate is 40.0%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top adaptogen supplier from India?

KERALA AYURVEDA LIMITED is the leading adaptogen exporter from India with a market share of 100.0% and total export value of $6.2K across 12 shipments. The top 5 suppliers together control 100.0% of total export value.

Suresh Sormare

Adaptogen

India Pharmaceutical Trade Intelligence

$6.2K1 Suppliers2 CountriesHS 30049011

ExportsIndia → UNITED STATES89.1%India → SINGAPORE10.9%

#1 Supplier: KERALA AYURVEDA #1 Buyer: SUVEDA INC.D/B/A

Adaptogen Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Adaptogen to the World

Between 2022 and 2026, India exported $6.2K worth of adaptogen across 12 verified shipments to 2 countries — covering 1% of world markets in the Ayurvedic & Herbal Products segment. The largest destination is UNITED STATES (89.1%). KERALA AYURVEDA LIMITED leads with a 100.0% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Adaptogen export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Adaptogen export data snapshot — $6.2K · 1 exporters · 2 countriesTransData Nexus · Indian Customs Data

Top Adaptogen Exporters from India

1 active exporters · Ranked by export value

View all 1 →

Top Adaptogen Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	KERALA AYURVEDA LIMITED	$6.2K	12	2	100.0%

Based on customs records from 2022 through early 2026, India's adaptogen export market is led by KERALA AYURVEDA LIMITED, which holds a share of all adaptogen exports — the largest of any single manufacturer over this period. The top 5 suppliers together account for of total export value, reflecting a concentrated supplier landscape among the 1 active exporters. Each supplier handles an average of , indicating selective, specialised distribution patterns.

Top Countries Importing Adaptogen from India

2 destination markets · Ranked by import value

All 2 countries →

Top Countries Importing Adaptogen from India — Ranked by Import Value
#	Country	Import Value (USD)	Shipments	Market Share
1	UNITED STATES	$5.5K	0	89.1%
2	SINGAPORE	$674	0	10.9%

UNITED STATES is India's largest adaptogen export destination, absorbing 89.1% of total exports worth $5.5K. The top 5 importing countries — UNITED STATES, SINGAPORE — together account for 100.0% of India's total adaptogen export value. The remaining -3 destination countries collectively receive the other 0.0%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Adaptogen

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, "Adaptogen" is not listed in the FDA's Orange Book, indicating no approved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for this product. Consequently, there are no therapeutic equivalence evaluations or reference listed drugs (RLDs) associated with "Adaptogen" in the U.S. market. This absence suggests that "Adaptogen" has not undergone the FDA's rigorous approval process required for marketing pharmaceutical products in the United States.

Given that "Adaptogen" is not FDA-approved, it is not subject to import alerts specific to this product. However, the importation of unapproved drugs into the U.S. is generally prohibited under the Federal Food, Drug, and Cosmetic Act. Importers must ensure compliance with FDA regulations to avoid potential enforcement actions. The limited export activity from India—comprising 12 shipments by a single exporter, Kerala Ayurveda Limited, primarily to the United States (89.1%)—underscores the niche market presence and potential regulatory challenges faced by "Adaptogen" in the U.S.

2EU & UK Regulatory Framework

In the European Union and the United Kingdom, pharmaceutical products must obtain marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) before commercialization. As of March 2026, there are no records of "Adaptogen" receiving such authorization, indicating it is not approved for sale in these regions.

Compliance with Good Manufacturing Practice (GMP) standards is mandatory for pharmaceutical products in the EU and UK. Manufacturers must adhere to these stringent guidelines to ensure product quality and safety. The absence of marketing authorization for "Adaptogen" suggests that it has not been evaluated against these regulatory standards, potentially limiting its market access in these regions.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. As of the latest edition, "Adaptogen" is not included in this list, indicating it is not recognized as an essential medicine globally.

Furthermore, "Adaptogen" has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, "Adaptogen" is not monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP), suggesting a lack of standardized quality benchmarks for this product.

4India Regulatory Classification

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. "Adaptogen" is not specifically listed under Schedules H, H1, or X, which pertain to prescription drugs with varying degrees of control. This classification implies that "Adaptogen" may be available over-the-counter (OTC) without a prescription.

The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the prices of essential medicines in India. As "Adaptogen" is not listed under the DPCO, it is not subject to price controls, allowing manufacturers to set prices freely. For export purposes, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is typically required, ensuring compliance with export regulations.

5Patent & Exclusivity Status

A search of the FDA's Orange Book reveals no patents or exclusivity periods associated with "Adaptogen," indicating the absence of patent protection in the U.S. market. This lack of exclusivity suggests that, should "Adaptogen" seek market entry, it would not face patent-related barriers, potentially allowing for generic competition upon approval.

6Recent Industry Developments

In June 2025, the Indian Ministry of Health and Family Welfare amended the Drugs and Cosmetics Rules to streamline the approval process for traditional medicines, including Ayurvedic products. This regulatory change aims to promote the export of such products by reducing bureaucratic hurdles.

In September 2025, the NPPA announced a revision of the National List of Essential Medicines (NLEM), adding several Ayurvedic formulations. While "Adaptogen" was not included, this development reflects a growing recognition of traditional medicines in India's healthcare system.

In December 2025, the WHO released updated guidelines on the quality control of herbal medicines, emphasizing the need for standardized testing methods. These guidelines are expected to influence regulatory frameworks globally, including in India, potentially impacting the manufacturing and export standards for products like "Adaptogen."

In February 2026, the EMA initiated a public consultation on the integration of traditional herbal medicines into the EU regulatory framework. This move indicates a potential shift towards greater acceptance and regulation of such products within the European market.

In March 2026, the U.S. FDA issued a draft guidance document outlining the regulatory considerations for botanical drug products, including those derived from traditional medicine practices. This guidance aims to clarify the approval pathway for such products, potentially affecting future market entry strategies for "Adaptogen" in the U.S.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Adaptogen

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of APIs used in Indian drug manufacturing are sourced from China, making the supply chain vulnerable to disruptions. This dependency was highlighted in June 2024 when environmental regulations in China led to the shutdown of several chemical plants, causing a significant shortage of KSMs and subsequent API supply constraints in India.

To mitigate such risks, the Indian government launched the Production Linked Incentive (PLI) scheme in October 2024, aiming to boost domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, reducing import dependence. However, the effectiveness of these initiatives in achieving self-sufficiency remains to be fully realized.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the export of "Adaptogen" from India is highly concentrated, with KERALA AYURVEDA LIMITED accounting for 100% of the export value. This single-source dependency poses significant risks, as any operational or quality issues within this sole supplier could disrupt the entire supply chain. The PLI scheme, while a step towards diversification, has yet to address this specific concentration risk in the adaptogen market.

Access Complete Adaptogen Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 12 transactions across 2 markets.

Request Demo View Pricing

Frequently Asked Questions — Adaptogen Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top adaptogen exporters from India?

The leading adaptogen exporters from India are KERALA AYURVEDA LIMITED. KERALA AYURVEDA LIMITED leads with 100.0% market share ($6.2K). The top 5 suppliers together control 100.0% of total export value.

What is the total export value of adaptogen from India?

The total export value of adaptogen from India is $6.2K, recorded across 12 shipments from 1 active exporters to 2 countries. The average shipment value is $516.

Which countries import adaptogen from India?

India exports adaptogen to 2 countries. The top importing countries are UNITED STATES (89.1%), SINGAPORE (10.9%), which together account for 100.0% of total export value.

What is the HS code for adaptogen exports from India?

The primary HS code for adaptogen exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Adaptogen

Adaptogen

How India Exports Adaptogen to the World

Top Adaptogen Exporters from India

Top Countries Importing Adaptogen from India

Quick Facts

Related Ayurvedic & Herbal Products

Related Analysis

Need Details?

Regulatory Landscape — Adaptogen

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Adaptogen

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Adaptogen Trade Intelligence

Frequently Asked Questions — Adaptogen Exports from India

Who are the top adaptogen exporters from India?

What is the total export value of adaptogen from India?

Which countries import adaptogen from India?

What is the HS code for adaptogen exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of adaptogen exports from India?

Which ports handle adaptogen exports from India?

Why is India a leading exporter of adaptogen?

What certifications do Indian adaptogen exporters need?

How many buyers import adaptogen from India?

What is the market share of the top adaptogen exporter from India?

Analysis Methodology